Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung

Pathology International

Volumn 63, Issue 2, 2013, Pages 77-84

  Shiozawa, Toshihiro ^a   Ishii, Genichiro ^a   Goto, Koichi ^a   Nagai, Kanji ^a   Mimaki, Sachiyo ^a   Ono, Shotaro ^a   Niho, Seiji ^a   Fujii, Satoshi ^a   Ohe, Yuichiro ^a   Tsuchihara, Katsuya ^a   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

EGFR mutation; Immunohistochemistry; Lepidic growth pattern; Lung adenosquamous carcinoma

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ADENOSQUAMOUS CARCINOMA OF THE LUNG; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; WEDGE RESECTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84874785589     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12033     Document Type: Article

References (30)

1. Travis WD, Branbilla E, Muller-Hermelink HK. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004.
2. Filosso PL, Ruffini F, Asioli S etal. Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. Lung Cancer 2011; 74: 25-29.
3. Cooke DT, Nguyen DV, Yang Y etal. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010; 90: 943-948.
4. Paez JG, Jänne PA, Lee JC etal. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
5. Lynch TJ, Bell DW, Sordella R etal. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
6. Pao W, Miller VA. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 16: 2256-2268.
7. Mitsudomi T, Kosaka T, Yatabe Y etal. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11: 190-198.
8. Sasaki H, Endo K, Fujii Y etal. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 2007; 55: 129-130.
9. Kang SM, Kang HJ, Shin JH etal. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007; 109: 581-587.
10. Sobin L, Wittekind C. TNM Classification of Malignant Tumors. New York: Wiley and Sons, 2002.
11. Tsuta K, Ishii G, Nitadori J etal. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 2006; 209: 78-87.
12. Shigematsu H, Lin L, Gazdar AF etal. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
13. Kancha RK, Peschel C, Duyster J etal. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol 2011; 6: 387-392.
14. Ohtsuka K, Ohnishi H, Fujiwara M etal. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: Tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007; 109: 741-750.
15. Toyooka S, Yatabe Y, Tomii K etal. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006; 118: 1588-1590.
16. Tochigi N, Dacic S, Nikiforova M etal. Adenosquamous carcinoma of the lung: A microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol 2011; 135: 783-789.
17. Jia XL, Chen G etal. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 2011 May 17(Epub) 74: 396-400.
18. Kozu Y, Tsuta K, Kohno T etal. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011; 73: 45-50.
19. Yu J, Kane S, Wu J etal. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 3023-3028.
20. Li D, Chen S, Hu C etal. Immunohistochemistry with mutation specific antibodies detecting the status of EGFR mutations in non-small-cell lung cancer. Mod Pathol 2010; 23: 407A.
21. Kato Y, Peled N, Wynes MW etal. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010; 5: 1551-1558.
22. Kitamura A, Hosoda W, Yatabe Y etal. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010; 16: 3349-3355.
23. Miyamae Y, Shimizu K, Hirato J etal. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011; 25: 921-928.
24. Rekhtman N, Paul K, Marc L etal. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous cell carcinoma of lung: Lack of EGFR/KRAS and preence of PIK3CA/ALT1 mutaions. Clin Cancer Res 2012; 18: 1167-1176.
25. Kanazawa H, Ebina M, Nukiwa T etal. Transition frm squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung. Am J Pathol 2000; 156: 1289-1298.
26. Blons H, Cote JF, Le CD etal. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol 2006; 30: 1309-1315.
27. Fukuoka M, Wu YL, Mok TS etal. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
28. Sonobe M, Kobayashi M, Date H etal. Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. Ann Surg Oncol 2011; May 24; 19: 347-353.
29. Mitsudomi T, Kosaka T, Yatabe Y etal. Mutation of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
30. Shukuya T, Takahashi T, Yamamoto N etal. Efficacy of gefitinib for non-adenocarcinoma non-small cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of previous reports. Cancer Sci 2011; 102: 1032-1037.